First Phase Of New MRIGlobal Diagnostics Center Of Excellence Opens
CAP/CLIA Laboratory Now Fully Operational; New Diagnostics Center at Headquarters Location Targeted for Completion in November 2019
KANSAS CITY, Mo., Aug. 27, 2019 /PRNewswire/ -- The first phase of a plan to establish a Diagnostics Center of Excellence at MRIGlobal's headquarters in Kansas City has been completed and is now fully operational.
MRIGlobal's College of American Pathologists (CAP) accreditation and Clinical Laboratory Improvement Amendments (CLIA) certification were completed in July.
The opening of the 1,100-square foot CAP/CLIA laboratory is the first step toward completion of a new Diagnostics Center of Excellence in lab space currently undergoing renovation and expansion. The new Center of Excellence will ultimately add 45 new highly skilled employees with advanced degrees and will attract millions in research and development dollars to the local economy.
Phase 1 and 2 are a result of growing demand for MRIGlobal's expertise in diagnostics research and clinical development and better equips the organization to solve its clients' problems in the areas of infectious disease detection, surveillance, and global bio-engagement.
MRIGlobal's CAP/CLIA lab uses sophisticated techniques, workflows, and approaches to assist with the development, evaluation, and validation of molecular diagnostic assays. CLIA federal regulations for clinical laboratories provide industry standards for testing of human samples for the purposes of diagnosis, prevention, treatment, or assessment of disease.
When Phase 2 of the Diagnostics Center of Excellence opens in November, it will occupy 7,500 square feet of newly renovated space with flexible, state-of-the-art laboratories designed specifically to support all phases of in vitro diagnostic product development.
"The addition of our CAP/CLIA lab to Kansas City is exciting because it means we're close to completing this important initiative that enables us to better respond to a growing and dynamic market," said Thomas Sack, Ph.D., MRIGlobal President and Chief Executive Officer. "We're eager to expand on the great work we're already doing in the diagnostics arena."
MRIGlobal manages a variety of large commercial in vitro diagnostic programs. In vitro diagnostics are tests performed on human blood or tissue for purposes of disease detection and monitoring. These programs range from the development of cutting edge, molecular-based assays focused on detecting low levels of highly pathogenic diseases to the advancement of novel, ultra-sensitive diagnostic panels for identifying and quantifying different strains of the influenza virus.
About MRIGlobal
Celebrating its 75th year of business, MRIGlobal addresses some of the world's greatest threats and challenges. Founded in 1944 as an independent, non-profit organization, we perform contract research for government, industry, and academia. Our customized solutions in national security and defense and health include research and development capabilities in clinical research support, infectious disease and biological threat agent detection, global biological engagement, in vitro diagnostics, and laboratory management and operations. MRIGlobal is one of two partners in the Alliance for Sustainable Energy, LLC, which manages and operates the National Renewable Energy Laboratory (NREL) in Golden, Colorado for the U.S. Department of Energy. For more information, visit www.mriglobal.org
SOURCE MRIGlobal
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article